Two new CareLink™ reports for MiniMed™ 670G system users

Woman using computer

In diabetes management, as in so many aspects of life, knowledge (and understanding) is power. Fortunately, CareLink™ software gives you valuable information to help you better understand your diabetes. With comprehensive, actionable insights based on your pump and CGM information, you and your healthcare team have what you need to collaborate how best to optimize your diabetes management. 

The revolutionary new MiniMed™ 670G system reveals important information about your individual diabetes. That’s why we now have two brand new CareLink™ reports that allow you to have a more productive conversation with your healthcare professional. These reports will help you spend less time looking at problems and more time evaluating solutions to maximize the impact of SmartGuard™ HCL technology.

Assessment & Progress report

Carelink assessment report


This new report lets you view information over time, celebrate daily diabetes wins, and identify opportunities to talk with your healthcare team. You can easily see the amount of time you’re spending between 70-180 mg/dL, which is called Time in Range. Rather than focusing on averages, Time in Range gives you a fuller picture of how much of your day is spent without highs and lows so you can spend more time living your life. 

You can learn more about this report by clicking here.

Weekly Review report

Carelink review report

This second report shows how much time you've spent in Manual Mode versus Auto Mode. The MiniMed™ 670G system with SmartGuard™ HCL technology has safety mechanisms in place that may exit you from Auto Mode in certain circumstances. In this report, the gray shading helps focus attention on when you were exited from Auto Mode and how much time was spent in Manual Mode. This helps you to evaluate the reasons for exits and identify ways to increase time in Auto Mode. 

You can learn more about this report by clicking here

We’d love to hear from you on these new reports. And maybe your thoughts will be used for future updates. 

1. CareLink™ reports are designed to provide better information and not just data.  What are your favorite parts of the new CareLink™ reports? 

2. CareLink™ software is a tool to help you better understand your diabetes. How do you use the information on CareLink™ reports? 

3. Every day is a new opportunity to celebrate what’s going well. What does the information in the CareLink™ reports mean to you? How does it make you feel? 

If it’s been a while since you’ve logged in, visit the CareLink™ website today. Need help logging in? Visit our support section. There is so much you can learn about day-to-day life with diabetes by looking at your pump and glucose data in a more holistic way. Enjoy the new reports and let us know if you have any questions!  

 

IMPORTANT SAFETY INFORMATION
 
CareLink® Therapy Management Software for Diabetes is intended to be used together with advice from a healthcare professional familiar with the diagnosis and treatment of diabetes. Do not make any changes to treatment without talking to a healthcare professional first. For more information, please visit www.medtronicdiabetes.com/about/safety.html.
The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.
 
The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).
 
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.
 
The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.
For complete safety information, please consult the appropriate User Guide.
 

Related Articles

About Author

Blog comments

Submitted by Stacey Palitza (not verified) on

In reply to by Commenter (not verified)

I need a pump but cant afford one can. I live on foodstamps i work but still cant afford a pump. If i dont get one son i will be on dialysis soon.

Submitted by Karrie Hawbaker (not verified) on

In reply to by Stacey Palitza (not verified)

Hi Stacey,
We offer financial assistance to those who qualify, which you can learn more about here http://bit.ly/180ygiz.

Submitted by Robin (not verified) on

In reply to by Commenter (not verified)

I have been using the 670G auto mode for 4 weeks now and it is amazing but I am concerned about the CareLink reporting that I can run being correct. Over the past 4 weeks I have been reporting my uploads to my Medtronic Diabetes Clinical Manager who trained me on the 670G and the Assessment & Progress report that she runs shows a different % of time in range than when I run the same report for the same time period myself on CareLink. For example when I run my CareLink report for the period 08/02/17 to 08/08/17 it shows me being in range 50% . The report for the exact timeframe that my Clinical Manager sent me shows that I am in range 79% How can this be?

Robin

Submitted by Karrie Hawbaker (not verified) on

In reply to by Robin (not verified)

Robin, the “Target Range” can be adjusted within CareLink Personal so you might just have different settings from your Diabetes Clinical Manager. They are likely using a BG target range of 70-180 mg/dL, which is the new default in CareLink online. If you used CareLink prior to starting the MiniMed 670G, then it’s probably reporting on the old range of 70-140 mg/dL. If you decide that you want to change the target at any time, click on “Preferences” in the top right-hand corner of CareLink and adjust the numbers in “BG Target Range High” box.

Submitted by Robin (not verified) on

In reply to by Karrie Hawbaker (not verified)

Thanks Karrie....That was exactly what it was!

Submitted by Kelly Rayhons (not verified) on

In reply to by Commenter (not verified)

Do any supplies from any other pumps work with the 670g? I want to switch but have a lot of supplies left.

Submitted by Karrie Hawbaker (not verified) on

In reply to by Kelly Rayhons (not verified)

Kelly, the MiniMed 670G system includes a different transmitter and an entirely new sensor but most ongoing supplies are the same. You can use any MiniMed infusion set and the 3.0 ml reservoir. If you decide to move forward with the new system, we can also work with you on return/exchanges as long as the supplies meet specific criteria.

Submitted by Kelly Rayhons (not verified) on

In reply to by Karrie Hawbaker (not verified)

Thank you!!!!

Submitted by JL Wilson (not verified) on

In reply to by Commenter (not verified)

I notice that my sensor is consistently indicating a BG that is about 15 or 20 points lower than my finger prick indicates. So on automode its actually keeping me near 140 or 150 rather than 120. I think even 120 is a little higher than my preferred level. Is there any chance that in the foreseeable future the software can be updated to adjust the target number?

Submitted by Karrie Hawbaker (not verified) on

In reply to by JL Wilson (not verified)

JL, thank you for your feedback! This blog may be helpful to better understand how the target algorithm works: https://www.medtronicdiabetes.com/loop-blog/10606-2/. Through all of the clinical studies we have done, the 120 mg/dL target has been effective and safe but can't be changed. We have heard feedback like yours and are always innovating.

Submitted by eric hwang (not verified) on

In reply to by Commenter (not verified)

Will the 670 and supplies be covered under Medicare medicad?

Submitted by Naomi Ruperto (not verified) on

In reply to by eric hwang (not verified)

Eric, at this time Medicare does not cover CGM for most customers. Medtronic is actively working with the Centers for Medicare & Medicaid Services (CMS) to ultimately establish coverage consistent with other healthcare insurance companies in the US. The first step is to work with CMS to assign CGM to a benefit category. We are excited to work this through with industry partners and will keep you updated.

Submitted by R McMahon (not verified) on

In reply to by Commenter (not verified)

hello, can you please make the overtape that is used with the Enlite sensor available for purchase ? Each pack of five sensors comes with a small envelope of ten overtapes. Using two overtapes per sensor means that there is no excess for those time when an overtape is spoiled. For example, if the tape sticks to itself at the time you are applying the overtape, it is easy to ruin it when you try to pull it apart. I've called Medtronic a couple of times with this question and have not had any luck receiving a favorable response to my suggestion that customers be able to purchase extra overtape. thanks

Submitted by Karrie Hawbaker (not verified) on

In reply to by R McMahon (not verified)

R, unfortunately at the moment the Enlite sensor overtape is not available for purchase separately. As soon as this changes, we will let you know.

Submitted by Katie Votodian (not verified) on

In reply to by Commenter (not verified)

Something I would like to see with carelink reports and the 670g system would be a long term analysis of my "basal" rates. Because the 670g uses the micro boluses it is sometimes disconcerting to go from automode to standard mode. I feel my basals were pretty well fine tuned prior to starting automode but I am curious how the automode might be finding any discrepancies. In the long run, I think this would be a useful way for me to feel more confident in my stability on those times when I do get kicked out of automode without my knowledge. This has happened to me a couple of times overnight. Fortunately for me, the accuracy of my basals prior to automode was a good place to begin but I know that patients who have not been on a pump long term have more trouble staying in automode. This type of report would likely help them.

Submitted by Katie Votodian (not verified) on

In reply to by Commenter (not verified)

Many pump users of the 630 and 670g have commented that it would make more sense for the screen to be read the opposite way. When I remove my pump from my side or pocket, I literally need an extra 2 - 3 inches of tubing in order to read my screen (roughly the length of the tubing to go from the reservoir connect down to the end of the pump). When you want to use short tubing so it doesn't catch on everything, those 2-3 inches makes a big difference. Please pass this recommendation to the product design team. Apparently no one really thinks about the way things work from a user perspective instead of a viewer/caregiver perspective.

Submitted by Karrie Hawbaker (not verified) on

In reply to by Katie Votodian (not verified)

Katie, thank you for the feedback and recommendation! We will pass this along to our research and development team. Understanding the varied needs of people with diabetes is incredible important to us. You may enjoy reading this blog to learn about how our customer experience feedback process works: https://www.medtronicdiabetes.com/loop-blog/what-the-customer-experienc….


Post a new comment

Required fields are marked *
The content of this field is kept private and will not be shown publicly.